Ocugen Gestione
Criteri Gestione verificati 1/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Shankar Musunuri
Amministratore delegato
US$4.8m
Compenso totale
| Percentuale dello stipendio del CEO | 15.65% |
| Mandato del CEO | 13yrs |
| Proprietà del CEO | 0.8% |
| Durata media del management | 1.2yrs |
| Durata media del Consiglio di amministrazione | 5.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Seeking Alpha • Sep 10
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts
Summary Ocugen, Inc. is maintained at a Hold rating due to mixed clinical progress and ongoing pivotal trials across its ophthalmology pipeline. The company's OCU400 gene-agnostic therapy for retinitis pigmentosa shows promise, with phase 3 liMeliGhT top-line data expected in Q1 2027 and strong phase 1/2 results. OCU410ST for Stargardt disease faces uncertainty after a negative interim analysis, but the phase 2/3 GARDian3 trial will continue with full sample assessment. OCGN's cash runway extends into 2028 following a $130M convertible note raise, reducing near-term dilution risk and supporting ongoing R&D. Read the full article on Seeking Alpha
Aggiornamento narrativa • Aug 16
OCGN: Upcoming Gene Therapy Readouts And RMAT Status May Re Rate Shares
Analysts lifted their Ocugen fair value estimate from $7.00 to $8.00 per share, citing updated assumptions around revenue growth, discount rate, profit margin, and a very large future P/E multiple that reflects the company’s clinical pipeline and upcoming trial milestones. Analyst Commentary Street research coverage on Ocugen remains active, with recent updates giving investors a mix of optimism around the clinical pipeline and a reminder of the risks that come with early stage biotech exposure.Aggiornamento narrativa • Aug 02
OCGN: Upcoming Gene Therapy Trials And RMAT Pathway Could Re Rate Shares
Ocugen's updated analyst price target has shifted modestly to $11 from $12, with analysts pointing to recent discussions on upcoming clinical milestones and trial preparations as the key reasons for refining their models. Analyst Commentary Recent commentary on Ocugen highlights a mix of interest in the clinical pipeline and caution around how that pipeline translates into long term value.
Aggiornamento narrativa • Jul 07
OCGN: Upcoming Retinal Trial Readouts Will Shape Future Upside Potential
Analysts raised their fair value estimate for Ocugen to about $20.62 from $15.00, citing updated assumptions for revenue potential, profitability, and a lower expected future P/E multiple based on recent clinical and regulatory progress discussed in recent research. Analyst Commentary Recent Street research on Ocugen shows a mix of optimism around the pipeline and caution around timing and execution, which together help explain the latest fair value revisions.
Aggiornamento narrativa • Jun 23
OCGN: Gene Therapy Pivotal Trials And 2027 Readouts Will Drive Repricing
Ocugen's analyst price target has shifted modestly, with one firm trimming its view from $12 to $11 while others recently raised their targets by $3 to $4. This reflects analysts' focus on the company's gene therapy pipeline, ongoing pivotal trials and upcoming clinical catalysts.Aggiornamento narrativa • Jun 05
OCGN: Retinal Gene Therapies Will Gain Momentum With Upcoming 2027 Readouts
Ocugen's analyst price target has edged down by $0.14 to $11.43 as analysts refresh their models around updated expectations for revenue growth, profitability, and long term P/E assumptions following recent gene therapy trial updates and upcoming catalysts across the retinal disease pipeline. Analyst Commentary Recent research updates show a mix of optimism around Ocugen's gene therapy pipeline and some caution on execution risk and timing, which is feeding into the modest reset in the average price target.Aggiornamento narrativa • Apr 26
OCGN: Retinal Gene Therapy Pipeline Will Drive Future Upside Potential
Narrative Update on Ocugen Analyst price targets for Ocugen have moved higher, with several recent increases of $3 to $7 tied to positive preliminary data for OCU410, expectations around OCU400 in retinitis pigmentosa, and a growing view of the company as an emerging player in gene therapy for blinding ocular disorders. Analyst Commentary Recent research coverage on Ocugen centers on its gene therapy pipeline and the implications for valuation if key clinical and regulatory milestones are met.Aggiornamento narrativa • Apr 11
OCGN: Late Stage Retinal Gene Therapies Will Drive Future Upside Potential
Ocugen's analyst price targets have moved higher by several dollars, with analysts pointing to Ocugen's Phase 3 OCU400 program, early OCU410 data and a perceived opportunity in retinal disease markets as key reasons for the updated views. Analyst Commentary Recent research coverage on Ocugen has leaned constructive, with several firms updating their models and price targets after new clinical data and program milestones.Aggiornamento narrativa • Mar 28
OCGN: Retinal Gene Therapy Milestones Will Drive Future Upside Potential
Ocugen's updated fair value estimate has shifted to $11.57 from $10.36 as analysts factor in a series of higher price targets on the stock, supported by recent positive clinical data and new coverage that highlights its gene therapy pipeline in retinal diseases. Analyst Commentary Recent research on Ocugen is clustered around its gene therapy portfolio in retinal diseases, with several firms updating models and targets after new data readouts and coverage initiations.Aggiornamento narrativa • Mar 12
OCGN: Late Stage Gene Therapy Progress Will Drive Future Upside Potential
Ocugen's analyst price target has moved higher toward $22, reflecting updated fair value estimates of about $10.36 per share and analyst focus on recent OCU410 Phase 2 data and OCU400's Phase 3 progress in blinding ocular disorders. Analyst Commentary Recent research on Ocugen centers on how the new OCU410 Phase 2 readout and the OCU400 Phase 3 program could influence valuation, risk, and execution over the next few years.Aggiornamento narrativa • Feb 25
OCGN: Trial Progress And CFO Appointment Will Support Future Upside Potential
Narrative update on Ocugen Analysts have made a modest adjustment to their Ocugen price target, keeping fair value around $9.00. Small tweaks to the discount rate and future P/E assumptions refine, rather than overhaul, their view on the stock.Aggiornamento narrativa • Feb 11
OCGN: Positive Trial Data And New CFO Appointment Will Drive Upside
Ocugen's updated analyst price target edges higher, with a new fair value estimate of $9.00 per share supported by slightly adjusted assumptions for the discount rate, long term revenue growth, profit margin, and future P/E multiple. This indicates analysts are fine tuning their models rather than making a major shift in view.Aggiornamento narrativa • Jan 27
OCGN: Positive Trial Data And Capital Raise Will Drive Future Upside
Narrative Update The analyst price target for Ocugen has been fine tuned by a few cents, with only marginal shifts in fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as analysts adjust their models in line with recent industry wide recalibrations seen in other coverage. Analyst Commentary Recent Street research on other companies in the broader building products and housing related space shows a mix of optimism on long term demand and caution around nearer term volatility.Aggiornamento narrativa • Jan 12
OCGN: Pipeline Milestones Will Drive Upside As Execution Risks Moderate
Analysts have trimmed their fair value estimate for Ocugen to $9.00. They link this move to slightly lower assumed discount rates and modest tweaks to long term revenue growth, profit margin, and future P/E expectations.Aggiornamento narrativa • Dec 15
OCGN: Pipeline Milestones Will Support Upside Despite Competitive And Capital Allocation Risks
Analysts have modestly trimmed their price target on Ocugen to around $9.00 per share. This reflects slightly lower discount rate and valuation assumptions as they factor in sustained but more competitively pressured growth and margins.Aggiornamento narrativa • Nov 29
OCGN: Exclusive Licensing Deal Will Drive Upside Amid Industry Headwinds
Ocugen's analyst price target remains steady at $9.00, as analysts cite ongoing competitive pressures and a lack of expected demand rebound in the sector as key factors for maintaining their current valuation outlook. Analyst Commentary Analyst sentiment around Ocugen reflects a balance of cautious optimism and ongoing concerns, shaped by sector-wide trends and company-specific challenges.Aggiornamento narrativa • Nov 15
OCGN: Upbeat Licensing Agreement Is Expected To Drive Shareholder Value In Coming Years
Narrative Update: Ocugen Analyst Price Target Revision Analysts have raised their price target for Ocugen from $8.20 to $9.00, citing increased revenue growth expectations and improved profit margin forecasts. Analyst Commentary Following the recent revision in Ocugen's price target, analysts have provided additional insight into the factors influencing their perspectives.Aggiornamento narrativa • Nov 01
OCGN: Future Licensing Deals And Regulatory Milestones Will Drive Long-Term Opportunity
Ocugen's analyst price target remained steady at $8.20, as analysts see unchanged fair value amid stable growth projections and profitability outlooks, according to recent reviews. Analyst Commentary Recent Street research provides a mixed outlook for Ocugen, reflecting both positive momentum and ongoing challenges as analysts assess the company's valuation and prospects for future growth.Aggiornamento narrativa • Oct 17
Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target was reaffirmed at $8.20, as analysts cite stable revenue growth and profit margin projections, with only minor changes to discount rate and future P/E assumptions supporting their steady outlook. Analyst Commentary Street research highlights a range of perspectives surrounding Ocugen’s outlook, as analysts weigh factors that could either support or limit future upside in the company’s valuation and execution.Aggiornamento narrativa • Oct 03
Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target has been raised significantly from $6.48 to $8.20, reflecting growing optimism among analysts based on stronger projected revenue growth and improving profit margins. Analyst Commentary Recent price target revisions signal a shift in analysts' outlook on Ocugen, highlighting both enthusiasm and lingering concerns regarding the company’s path forward.
Nuova narrativa • Apr 02
Gene Therapy Advances Will Unlock New Treatment Options
Advancing gene therapies for unmet needs may drive significant future revenue growth and market share if upcoming products secure approvals.Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$82m |
| Mar 31 2026 | n/a | n/a | -US$72m |
| Dec 31 2025 | US$5m | US$758k | -US$68m |
| Sep 30 2025 | n/a | n/a | -US$64m |
| Jun 30 2025 | n/a | n/a | -US$57m |
| Mar 31 2025 | n/a | n/a | -US$58m |
| Dec 31 2024 | US$2m | US$758k | -US$54m |
| Sep 30 2024 | n/a | n/a | -US$51m |
| Jun 30 2024 | n/a | n/a | -US$50m |
| Mar 31 2024 | n/a | n/a | -US$58m |
| Dec 31 2023 | US$5m | US$758k | -US$63m |
| Sep 30 2023 | n/a | n/a | -US$79m |
| Jun 30 2023 | n/a | n/a | -US$90m |
| Mar 31 2023 | n/a | n/a | -US$86m |
| Dec 31 2022 | US$8m | US$715k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$74m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$69m |
| Dec 31 2021 | US$8m | US$541k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$2m | US$500k | -US$34m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$18m |
| Dec 31 2019 | US$572k | US$420k | -US$20m |
Compensazione vs Mercato: La retribuzione totale di Shankar ($USD 4.84M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.41M ).
Compensazione vs guadagni: La retribuzione di Shankar è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Shankar Musunuri (62 yo)
13yrs
Mandato
US$4,841,822
Compensazione
Dr. Shankar Musunuri, Ph D., MBA, is Co-Founder of OrthoCellix, Inc. and serves as its Chairman, Chief Executive Officer President and Secretary. Dr. Musunuri is the Co-Founder of Ocugen, Inc. since Septem...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 13yrs | US$4.84m | 0.84% $ 2.9m | |
| Chief Scientific Officer and Head of Research & Development | 4yrs | US$2.14m | 0.063% $ 220.9k | |
| CFO & Principal Accounting Officer | less than a year | Nessun dato | 0.15% $ 537.0k | |
| Executive Vice President of Operations | less than a year | Nessun dato | Nessun dato | |
| General Counsel | no data | Nessun dato | Nessun dato | |
| VP of Corporate Communications | less than a year | Nessun dato | Nessun dato | |
| Head of People & Culture | 2.4yrs | Nessun dato | Nessun dato | |
| Chief Development Officer | 1.2yrs | US$1.31m | Nessun dato | |
| Chief Medical Officer | less than a year | Nessun dato | Nessun dato | |
| VP & Head of Regulatory & Quality | 3.6yrs | Nessun dato | Nessun dato | |
| VP, Head of Program Management & Chief of Staff | 2.7yrs | Nessun dato | Nessun dato | |
| Executive Vice President of Commercial and Business Development | 1.2yrs | Nessun dato | Nessun dato |
1.2yrs
Durata media
55.5yo
Età media
Gestione esperta: Il team dirigenziale di OCGN non è considerato esperto (durata media 1.2 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 7yrs | US$4.84m | 0.84% $ 2.9m | |
| Member of Retina Scientific Advisory Board | 6.8yrs | Nessun dato | Nessun dato | |
| Member of Retina Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Vaccine Scientific Advisory Board Member | 5.8yrs | Nessun dato | Nessun dato | |
| Co-founder & Independent Director | 7yrs | US$211.25k | 0.21% $ 726.2k | |
| Vaccine Scientific Advisory Board Member | 5.8yrs | Nessun dato | Nessun dato | |
| Independent Director | 1.3yrs | US$182.32k | 0% $ 0 | |
| Independent Director | 7yrs | US$196.25k | 0.40% $ 1.4m | |
| Independent Director | 6.4yrs | US$203.75k | 0.022% $ 77.3k | |
| Independent Director | 1.3yrs | US$205.18k | 0% $ 0 | |
| Vaccine Scientific Advisory Board Member | 5.8yrs | Nessun dato | Nessun dato | |
| Chair of Retina Scientific Advisory Board | 2.3yrs | Nessun dato | Nessun dato |
5.8yrs
Durata media
60.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di OCGN sono considerati esperti (durata media dell'incarico 5.8 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/12 04:24 |
| Prezzo dell'azione a fine giornata | 2026/09/11 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Ocugen, Inc. è coperta da 7 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Elemer Piros | Lucid Capital Markets |